$EVO

Evotec SE

Evotec is a drug discovery and development company based in Hamburg, Germany. It serves pharmaceutical and biotechnology firms, academic institutions, patient advocacy groups and venture capital organizations. Its operations include Shared R&D and Just - Evotec Biologics. The company develops pharmaceutical products across areas including cancer, autoimmune conditions, diabetes, infectious diseases, neurological disorders and rare diseases. Its work also covers animal and women’s health.

AlphAI earnings read9M 2026 · NOV 5NINE-MONTH 2026 RESULTS ABOVE MARKET EXPECTATIONS; FULL-YEAR 2026 GUIDANCE REAFFIRMEDVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

4
1
0

No SEC Form 4 filings for $EVO in the last 30 days.

See all $EVO insider activity →
Med

Evotec and Bristol Myers Squibb Advance Strategic Protein Degradation Partnership with Second IND Acceptance

Evotec (EVO) and Bristol Myers Squibb received FDA clearance for a second Investigational New Drug (IND) in their protein degradation partnership. The first candidate entered Phase 1 trials in March 2026, and the second is expected to start in 2027. The collaboration leverages Evotec's drug discovery capabilities and Bristol Myers Squibb's CELMoD agent library to develop molecular glue degraders for oncology and other therapeutic areas.

Evotec Secures $2.9 Million Grant to Advance Early Drug Safety Testing Using Human Stem Cell Technology

Evotec SE (EVO) received a $2.9M grant from the Gates Foundation to continue developing its human stem cell-based platform for early drug safety testing. The three-year project aims to assess fetal development risks in novel drug candidates, building on a 2023 collaboration. Evotec's technology combines hiPSC models with industrial-scale screening to improve drug discovery efficiency.

The Board of Directors of Evolution AB (publ) has resolved on the continuance of the previously announced EUR 2 billion Share Buyback Program

Evolution AB's board approved the continuation of its EUR 2 billion share buyback program, with EUR 675.3 million remaining. As of November 6, 2026, the company repurchased 19.4 million shares for EUR 1.32 billion. The buyback will follow EU regulations and be executed by Citigroup. The maximum number of shares to be repurchased is 15.1 million, with acquisitions made on Nasdaq Stockholm.

EVO sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 5 news stories mentioning EVO (Evotec SE). Coverage has skewed bullish: 4 bullish, 1 neutral, and 0 bearish.

Recent EVO coverage spans technology, financial news and earnings.

What's driving EVO

  • Positive catalyst as the partnership shows repeatable success, likely supporting Evotec's share price.

    prnewswire.com · Nov 19, 2026

  • The grant adds non‑dilutive cash and validates Evotec's NAM platform, likely supporting short‑term share price stability or modest upside.

    prnewswire.com · Nov 16, 2026

  • Continuation of the buyback should provide ongoing bid support and signal capital-return commitment, though it is not a new authorization beyond the remaining tranche.

    tradingview.com · Nov 8, 2026

  • Guidance suggests modest upside but acknowledges variability and upcoming capital expenditures, likely leading to neutral to slightly negative price pressure.

    finance.yahoo.com · Nov 5, 2026

  • Evotec SE (EVO) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 For further information, please contact : Dr. Sarah Fakih, EVP Head of Global Communications and Investor Relations, sarah.fakih@evotec.com, M. +49.(0)151 70 688 784, www.evotec.com INTERIM STATEMENT 9M 2026 HIGHLIGHTS 4 D&PD LEADING COMMERCIAL INDICATORS SHOW CONTIN

    SEC EDGAR 6-K · Nov 5, 2026

AlphAI scores every news story that mentions EVO with an AI model for sentiment and relevance, and aggregates insider trades from Evotec SE's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $EVO

Score
$EVOMedAI 8/10Clinical / regulatory

Evotec and Bristol Myers Squibb Advance Strategic Protein Degradation Partnership with Second IND Acceptance

Evotec (EVO) and Bristol Myers Squibb received FDA clearance for a second Investigational New Drug (IND) in their protein degradation partnership. The first candidate entered Phase 1 trials in March 2026, and the second is expected to start in 2027. The collaboration leverages Evotec's drug discovery capabilities and Bristol Myers Squibb's CELMoD agent library to develop molecular glue degraders for oncology and other therapeutic areas.

$EVOLowContract· supplier · $2.9M

Evotec Secures $2.9 Million Grant to Advance Early Drug Safety Testing Using Human Stem Cell Technology

Evotec SE (EVO) received a $2.9M grant from the Gates Foundation to continue developing its human stem cell-based platform for early drug safety testing. The three-year project aims to assess fetal development risks in novel drug candidates, building on a 2023 collaboration. Evotec's technology combines hiPSC models with industrial-scale screening to improve drug discovery efficiency.

The Board of Directors of Evolution AB (publ) has resolved on the continuance of the previously announced EUR 2 billion Share Buyback Program

Evolution AB's board approved the continuation of its EUR 2 billion share buyback program, with EUR 675.3 million remaining. As of November 6, 2026, the company repurchased 19.4 million shares for EUR 1.32 billion. The buyback will follow EU regulations and be executed by Citigroup. The maximum number of shares to be repurchased is 15.1 million, with acquisitions made on Nasdaq Stockholm.

What Evotec (EVO) Said on Its Q3 Earnings Call

Evotec (EVO) expects Q4 revenue and profitability to decline due to lower milestone contributions. Net sales in D&PD base business rose 24% YoY in the first nine months. The company plans a manufacturing expansion in 2027 and has achieved 20% of its €75M annual savings target. Evotec reiterated its 2030 revenue goal of €1B and a 20% EBITDA margin by 2030.

MedEarnings

Evotec SE (EVO): Financial results for H2 2026

Evotec SE (EVO) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 For further information, please contact : Dr. Sarah Fakih, EVP Head of Global Communications and Investor Relations, sarah.fakih@evotec.com, M. +49.(0)151 70 688 784, www.evotec.com INTERIM STATEMENT 9M 2026 HIGHLIGHTS 4 D&PD LEADING COMMERCIAL INDICATORS SHOW CONTIN

Evotec Announces Chief Scientific Officer Transition

Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) announced that Dr. Cord Dohrmann will step down as Chief Scientific Officer on September 30, 2026. The decision was mutual, and the company is searching for a successor. Dr. Dohrmann served for 16 years, contributing to scientific advancements. Evotec's CEO praised his role in strengthening the company's scientific capabilities. The company's future growth is expected to rely on the science infrastructure built by Dr. Dohrmann.

Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors

Evotec SE (EVO) and Plectonic Biotech have entered a research collaboration to explore a new immunotherapy approach for solid tumors. The partnership combines Evotec's BiTco platform, which enhances T cell activation, with Plectonic's LOGIBODY® technology, designed for precise tumor recognition. The goal is to improve the precision and potency of T-cell-engaging therapies. Preclinical data will be generated to evaluate the potential of this combined approach.

Related tickers